Précédent|Prochain

Étude du rôle de la médecine traditionnelle chinoise dans la régulation de l'inflammation immunitaire et des lésions microvasculaires dans la prévention des rechutes post-pneumonie basée sur la théorie de « cause et effet »

  • role： First author第一作者
  • Affiliation：

    Tianjin University of Traditional Chinese Medicine（TCM），Tianjin 301617，China

  • Email：1424762138@qq.com
  • Introduction：彭鑫，在读博士，从事中医肺病临床研究，E-mail：1424762138@qq.com
PENG Xin1,  
  • Affiliation：

    Tianjin University of Traditional Chinese Medicine（TCM），Tianjin 301617，China

XU Haotian1,  
  • Affiliation：

    Tianjin University of Traditional Chinese Medicine（TCM），Tianjin 301617，China

LIANG Lei1,  
  • Affiliation：

    Tianjin University of Traditional Chinese Medicine（TCM），Tianjin 301617，China

LUAN Zheyu1,  
  • Affiliation：

    Tianjin University of Traditional Chinese Medicine（TCM），Tianjin 301617，China

WANG Hanxiao1,  
  • Affiliation：

    Tianjin University of Traditional Chinese Medicine（TCM），Tianjin 301617，China

YANG Kun1,  
  • role： Corresponding author通信作者
  • Affiliation：

    The Second Affiliated Hospital of Tianjin University of TCM，Tianjin 300250，China

  • Email：493507647@qq.com
  • Introduction：封继宏，博士，主任医师，博士生导师，从事中医肺病临床研究，E-mail：493507647@qq.com
FENG Jihong2*

résumé

La pneumonie est une maladie infectieuse présentant un taux élevé d'incidence et de mortalité dans le monde, et ses dommages au corps ne se limitent pas à la phase aiguë. La théorie « cause et effet » souligne la stagnation des agents pathogènes anciens dans le corps et l'activation de nouveaux agents pathogènes, combinant les anciens et les nouveaux pour provoquer la maladie, ce qui est une synthèse élevée du concept de pathogénie durant la phase de récupération de la pneumonie. Pendant la récupération de la pneumonie, le corps présente des altérations pathologiques telles que la perturbation de l'homéostasie immunitaire, une inflammation chronique de bas grade et des lésions microvasculaires, qui affectent continuellement la fonction corporelle, la santé des patients et leur qualité de vie, augmentant le risque d'infections secondaires. La médecine traditionnelle chinoise considère la pneumonie comme une maladie causée par une insuffisance, la phase de récupération étant caractérisée principalement par un « vide de Qi et une stase sanguine ». À ce stade, l'énergie défensive du corps est insuffisante et les agents pathogènes résiduels ne sont pas complètement éliminés, ce qui facilite la sensibilité aux facteurs pathogènes externes et la récurrence de la pneumonie. La « prévention des rechutes après guérison », en tant que partie importante du concept de « traiter la maladie avant qu'elle ne survienne » en médecine traditionnelle chinoise, insiste sur l'importance d'une gestion soignée après la guérison pour prévenir les récidives pendant la phase de récupération. Cet article, basé sur la théorie de « cause et effet », cible les caractéristiques pathogéniques de « vide de Qi et stase sanguine », explorant le rôle et la signification de la régulation de l'inflammation immunitaire et des lésions microvasculaires par la médecine traditionnelle chinoise dans la prévention des rechutes après pneumonie, afin d'élargir de nouvelles perspectives pour une prévention et un traitement efficaces pendant la récupération.

mots-clés

cause et effet; inflammation immunitaire et lésions microvasculaires; phase de récupération de la pneumonie; prévention des rechutes post-guérison; étude théorique

References

  1. 1.
    TORRES A，CILLONIZ C，NIEDERMAN M S，et al.Pneumonia［J］.Nat Rev Dis Primers，2021，7（1）：25.
  2. 2.
    GBD 2021 Causes of Death Collaborators.Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations，1990-2021：A systematic analysis for the Global Burden of Disease Study 2021［J］.Lancet，2024，403（10440）：2100-2132.
  3. 3.
    OLIVEIRA E SILVA P G，CERQUEIRA BATISTA FILHO L A，ISMAEL P F，et al.Community-acquired pneumonia：Epidemiology，diagnosis，prognostic severity scales，and new therapeutic options［J］.Medwave，2023，23 （11）：e2719.
  4. 4.
    GUO A，ZHANG S，FENG J H，et al.To explore the rehabilitation practice of integtated traditional Chinese and Western medicine for COVID-19 from the new understanding of the course of pneumonia［J］.Tianjin J Tradit Chin Med，2022，39（7）：841-845.
  5. 5.
    STOTTS C，CORRALES-MEDINA V F，RAYNER K J.Pneumonia-induced inflammation，resolution and cardiovascular disease：Causes，consequences and clinical opportunities［J］.Circ Res，2023，132 （6）：751-774.
  6. 6.
    CORRALES-MEDINA V F，DEKEMP R A，Chirinos J A，et al.Persistent lung inflammation after clinical resolution of community-acquired pneumonia as measured by 18FDG-PET/CT imaging［J］.Chest，2021，160（2）：446-453.
  7. 7.
    YENDE S，D'ANGELO G，MAYR F，et al.Elevated hemostasis markers after pneumonia increases one-year risk of all-cause and cardiovascular deaths［J］.PLoS One，2011，6 （8）：e22847.
  8. 8.
    HU F F，ZHAO Y，LI M H，et al.Adverse effects of long COVID and its countermeasures：A review［J］.Chin J Pub Health，2022，38（9）：1229-1232.
  9. 9.
    CHEN J，LIU X D，ZHANG S.Analysis of the connotation of traditional chinese medicine "Preventive Treatment" and exploration of development strategies in the new era［J］.Lishizhen Med Mater Med Res，2021，32（7）：1701-1703.
  10. 10.
    LI J S，WANG M H.Strategies and practice of traditional Chinese medicine for prevention and treatment of community-acquired pneumonia based on stages and severity［J］.J Tradit Chin Med，2024，65（16）：1662-1666.
  11. 11.
    ZHOU J P，WANG X P.Analysis on view of combining pathogenic factors in Huangdi Neijing［J］.China J Tradit Chin Med Pharm，2021，36（9）：5233-5236.
  12. 12.
    BAO L Y.Studies on onset theory about combination of pathogenic factors in Canon［D］.Jinan：Shandong University of Traditional Chinese Medicine，2018.
  13. 13.
    XIONG Y，MOU F Z.Origin and application of TCM thought of "treatment of the pro-disease"［J］.Acta Chin Med，2017，32（10）：1931-1933.
  14. 14.
    LI Z H，WANG Y L.Make textual criticisms and explanations of ci（疵），chai（瘥），fei（痱） in Er Ya connected with Commentaries on ancient disease names and syndrome［J］.Jilin Journal of Chinese Medicine，2016，36（3）：310-315.
  15. 15.
    HUANG Q S，AN X，XIE C G，et al.Traditional Chinese medicine treatment of nucleic acid recurrence in patients with COVID-19 is based on the theory of "disease recurrence caused by overwork after recovery" in Shanghan Lun［J］.Pharmacol Clin Chin Mater Med，2020，36（2）：15-17.
  16. 16.
    SHI W J，YU X Y，KOU L H，et al.Clinical application of traditional Chinese medicine aftercare thinking［J］.China J Tradit Chin Med Pharm，2023，38（4）：1667-1670.
  17. 17.
    KE L Z，LUO L，WANG D X，et al.On the guiding role of theory in preventive treatment of disease “preventing an attack of an old disease”of tumor recurrence and metastasis［J］.J Guizhou Univ Tradit Chin Med，2015，37（2）：1-5.
  18. 18.
    Anonymous.Diagnostic basis，syndrome classification and curative effect evaluation standard of wind-warm disease with lung heat：The standard of TCM internal medicine diagnosis and curative effect（ZY/T001.1-94）［J］.J Liaoning Univ Tradit Chin Med，2013，15（4）：7.
  19. 19.
    HUANG J H，BAI S L，LIU R.Discussion on TCM treatment of pulmonary diseases based on the theory of "Qi and blood"［J］.Shaanxi J Tradit Chin Med，2023，44（4）：483-486.
  20. 20.
    FENG J H，LIU N F，YANG S，et al.A Clinical efficacy study of Fuzheng Jiedu method in the treatment of community-acquired pneumonia based on "real world"［J］.Lishizhen Med Mater Med Res，2020，31（1）：121-124.
  21. 21.
    LI M F，FENG J H，HUANG Y H，et al.Idea for preventing recurrence of pneumonia by invigorating Qi and activating blood circulation method based on regulation of immune inflammation and microvascular damage［J］.Liaoning J Tradit Chin Med，2024，51（8）：45-47.
  22. 22.
    DARDEN D B，KELLY L S，FENNER B P，et al.Dysregulated immunity and immunotherapy after sepsis［J］.J Clin Med，2021，10 （8）：1742.
  23. 23.
    ZHANG W Z，WANG Z B.Research progress on the dyshomeostasis of effector T cell subsets related to immunosuppression in sepsis［J］.Chin Critic Care Med，2022，34（1）：95-99.
  24. 24.
    ZHANG Y C，YANG R L.Progress in immune disorders，immune monitoring and immunotherapy of severe infections［J］.Nation Med J China，2016，96（21）：1708-1712.
  25. 25.
    LUAN Z Y，WANG H X，PENG X，et al.To explore immune-inflammation mechanism of viral pneumonia and TCM treatment based on theory of "healthy Qi and pathogenic Qi"［J］.Chin J Exp Tradit Med Form，2025，31（2）：239-247.
  26. 26.
    LIANG X H.The study on the relationship between the constitution typesof traditional Chinese medicine and related immune function with the recovery of pneumonia in children［D］.Guangzhou：Guangzhou University of Chinese Medicine，2010.
  27. 27.
    LI Q，ZHANG H，DENG S Y，et al.Comparison of the expression and morphological characteristics of peripheral blood lymphocyte subsets in patients with positive recovery and negative patients during COVID-19 recovery period［J］.Chongqing Med J，2020，49（19）：3151-3155.
  28. 28.
    JIA Y T，LI X Q.Risk factors for respiratory tract infections in children during recovery stage［J］.Chin J Nosocomiol，2014，24（14）：3603-3604，3618.
  29. 29.
    GENG H J，XIE Y M.Discussion on the mechanism of immune function regulation of traditional Chinese medicine in convalescent and discharged patients with new coronavirus pneumonia［J］.World Sci Technol Mod Tradit Chin Med，2021，23（2）：482-487.
  30. 30.
    CHEN O L，WANG Z L.Research progress of microinflammatory state and disease severity in patients with chronic obstructive pulmonary disease［J］.J Clin Med Pract，2024，28（6）：139-142，148.
  31. 31.
    LUO Y L，ZHOU X T，WEI B J，et al.Understanding of inflammatory microenvironment and malignant transformation of inflammation in traditional Chinese medicine［J］.Lishizhen Med Mater Med Res，2022，33（8）：1966-1968.
  32. 32.
    MENG J W，SUI G Y，JIA L Q.Exploring the relationship between endothelial cell homeostasis and pan-vascular diseases based on the "Ying in the vessels" theory.［J］.Lishizhen Med Mater Med Res，2023，34（3）：655-657.
  33. 33.
    SHAO S S，YIN H M，YANG J L，et al.Protective effect of tanshinone ⅡA on pulmonary microvascular endothelial cell injury in sepsis［J］.J Emerg Tradit Chin Med，2024，33（4）：591-594，624.
  34. 34.
    CAO J，QIN J M，XUE W Z.Recent advances in the pathogenesis of coronary microvascular disease：The role of inflammatory reactions［J］.Med J Peking Union Med Coll Hos，2022，13（6）：1057-1063.
  35. 35.
    CHIOH F W，FONG S W，YOUNG B E，et al.Convalescent COVID-19 patients are susceptible to endothelial dysfunction due to persistent immune activation［J］.Elife，2021，10：e64909.
  36. 36.
    QI P，ZHU H Y.Research progress of long-COVID related cardiovascular disease［J］.Chin J Nosocomiol，2024，34（8）：1276-1280.
  37. 37.
    OIKONOMOU E，SOUVALIOTIS N，LAMPSAS S，et al.Endothelial dysfunction in acute and long standing COVID-19：A prospective cohort study［J］.Vascul Pharmacol，2022，144：106975.
  38. 38.
    WU Y，LEI Y，XIU C K，et al.Advances in research on the protective effect of Yiqi Huoxue method on vascular injury［J］.J Basic Chin Med，2021，27（5）：882-886.
  39. 39.
    CAI S Q，WANG X，SHANG M Y，et al."Efficacy theory" may help to explain characteristic advantages of traditional Chinese medicines［J］.China J Chin Mater Med，2015，40（17）：3435-3443.
  40. 40.
    WANG B H，SHI S F，ZHANG X N.Exploration on mechanism of Futu Shengjin rehabilitation formula in regulating immune function during COVID-19 convalescence based on the network pharmacology［J］.J Nanjing Univ Tradit Chin Med，2021，37（1）：91-95.
  41. 41.
    SHI S F，FANG Z Y，XIONG K，et al.Clinical observation of the rehabilitation formula for banking up earth to generate metal in treating COVID-19 patients with deficiency of lung and spleen syndrome in the recovery stage［J］.J Nanjing Univ Tradit Chin Med，2020，36（3）：281-285.
  42. 42.
    CHEN H，QIAO M，ZHU J H，et al.Effect of Feikang Yangyin granule on pulmonary disease in convalescence based on immune regulation［J］.J Pract Tradit Chin Intern Med，2022，36（3）：23-26.
  43. 43.
    CUI Y T，FAN Y H，DU G H，et al.Research progress on immunomodulatory effect of Chinese patent medicine containing astragalus on week health and susceptible persons［J］.J Shanxi Univ Chin Med，2022，23（4）：386-392.
  44. 44.
    WEN J W，FENG Y P，SHEN Z H，et al.Effect of total flavonoids of astragalus membranaceus on immune function and cytokines in rats with pneumocystis pneumonia［J］.Chin J Control Endem Dis，2023，38（4）：335-337.
  45. 45.
    QIAO M，GAN Y，ZHU J H，et al.Protective effect of Feikang Yiqi granule on lipopolysaccharide-induced acute lung injury in rats and immunomodulatory effect［J］.Liaoning J Tradit Chin Med，2022，49（4）：190-193.
  46. 46.
    GAN Y，SHI Y，QIAO M，et al.Protective effect of Feikang Yiqi granule on lipopolysaccharide-induced acute lung injury in rats and immunomodulatory effect［J］.Liaoning J Tradit Chin Med，2022，24（1）：22-25.
  47. 47.
    XIA H N.Study on the mechanism of Xiaochaihu decoction ininhibiting pulmonary inflammation during the recoveryperiod of COVID-19［D］.Dalian：Dalian Medical University，2023.
  48. 48.
    GUO S，WU W X，XIE H，et al.Molecular mechanism of Bufei Huoxue capsule on COVID-2019 based on network pharmacology and molecular docking［J］.Chin Tradit Herb Drug，2020，51（9）：2307-2316.
  49. 49.
    YANG L，LI M Y，HU W Q，et al.HPLC-Q-TOF-MS/MS and network pharmacology reveal absorbed components of Bufei pills，potential in treating respiratory disorders，and mechanism in recovery stage of COVID-19［J］.China J Chin Mater Med，2024，49（20）：5598-5609.
  50. 50.
    LV N，YUE B S，ZHANG W H，et al.Mechanism of Xuanfei Dayu decoction in treating the recovery stage of COVID-19 based on network pharmacology and molecular docking technology［J］.China Pharm，2021，24（11）：2002-2011.
  51. 51.
    YIN Y Y，YUE Z D，DING Y，et al.Study on the mechanism of Buzhong Yiqi decoction on the recovery period of COVID-19 based on network pharmacology［J］.J Shandong Univ Tradit Chin Med，2021，45（5）：685-694.
  52. 52.
    CHEN R L，CAO F，TONG H S，et al.Effects of Shengmai injection on LPS-induced inflammatory response and vascular endothelial cell injury in septic rats［J］.J Clin Emerg，2016，17（8）：621-624.
  53. 53.
    TIAN Y，LI R M，REN H W，et al.Feasibility of Shengmai powder in convalescent patients with novel coronavirus pneumonia［J］.Drug Eval Res，2020，43（3）：378-383.
  54. 54.
    GONG P Y，XIAO G X，LI W J，et al.Analysis of the mechanisms of Guanxinning tablet for antithrombotic and microthrombotic effects caused by COVID-19 based on network pharmacology［J］.Acta Pharm Sin，2024，59（9）：2545-2555.
  55. 55.
    BAI Z，LI P，WEN J，et al.Inhibitory effects and mechanisms of the anti-covid-19 traditional Chinese prescription，Keguan-1，on acute lung injury［J］.J Ethnopharmacol，2022，285：114838.
  56. 56.
    WANG J B，WANG Z X，JING J，et al.Exploring an integrative therapy for treating COVID-19：A randomized controlled trial［J］.Chin J Integr Med，2020，26 （9）：648-655.
  57. 57.
    WANG H X，LUAN Z Y，FENG J H.Role of supplementing Qi and activating blood in preventing relapse after recovery of community-acquired pneumonia with syndrome of lung deficiency and collateral stasis［J］.Chin J Exp Tradit Med Form，2024，30（14）：232-239.
  58. 58.
    XIONG F，GONG P，LIU Y J，et al.To analyze the feasibility of blood-activating and stasis-removing Chinese hebal drugs in the treatment of COVID-19 during convalescence［J］.Res Integr Tradit Chin West Med，2020，12（4）：272-275.
  59. 59.
    CHEN X X，HAN S，FAN G H，et al.Research progress of modern pharmacology of traditional Chinese medicine for promoting blood circulation and removing stasis［J］.Tianjin J Tradit Chin Med，2023，40（2）：250-257.
  60. 60.
    MAO M L，XIE L Y，LUO W K，et al.Research progress on pharmacological mechanisms of Danshen（Salviae Miltiorrhizae Radix et Rhizoma） and its active ingredients on cardiovascular system［J］.Chin Arch Tradit Chin Med，2024，42（7）：120-124.
  61. 61.
    XU W T，WANG X F.Observation on the effect of blood-activating/stasis-resolving Chinese herbal drugs in the treatment of persistent pneumonia in children［J］.Guangxi J Tradit Chin Med，2017，40（5）：3-5.
  62. 62.
    GUO J N，BAI X，ZHANG H X，et al.Discussion on treating pediatric pneumonia convalescence from stagnant heat based on the concept of preventing disease from exacerbating［J］.China J Tradit Chin Med Pharm，2023，38（10）：4742-4745.
  63. 63.
    MO M H.Compound salvia miltiorrhiza injection in the treatment of 50 children with pneumonia in the recovery period of rales［J］.J Tradit Chin Med，2008，49（2）：146.
  64. 64.
    LI N，SHENG K J，PENG G X，et al.Effect of Shenfu injection assisted with antibiotics on the subsided time of clinical symptoms，endothelial cell damage factor and pulmonary function in elderly patients with severe pneumonia［J］.Practical Geriatrics，2019，33（8）：764-767.
  65. 65.
    ROMERO-DUARTE Á，RIVERA-IZQUIERDO M，GUERRERO-FERNÁNDEZ DE ALBA I，et al.Sequelae，persistent symptomatology and outcomes after COVID-19 hospitalization：The ANCOHVID multicentre 6-month follow-up study［J］.BMC Med，2021，19（1）：129.
  66. 66.
    TIAN Y，ZHANG S，ZHENG W K，et al.Qingjin Yiqi granule in the treatment of low fever in convalescence of COVID-19（Omicron）：A case report［J］.Tianjin J Tradit Chin Med，2022，39（6）：692-696.
  67. 67.
    JIANG N，WANG K，LI X D，et al.Study on the distribution and evolution of traditional Chinese medicine syndromes in patients infected with the SARS-CoV-2 Omicron variant after nucleic acid turned negative［J］.Tianjin J Tradit Chin Med，2023，40（2）：140-145.
  68. 68.
    WANG Q L，SUN L F，ZHAO M F，et al.Application of TCM comprehensive rehabilitation system in the treatment of new coronavirus pneumonia in convalescence［J］.J Sichuan Tradit Chin Med，2023，41（6）：110- 114.
  69. 69.
    DU B Y，GAO J，LIU C Y，et al.Observation of the curative effect of Yupingfeng granule and Spleen Aminopeptide in the children with pneumonia and syndrome of lung-spleen deficiency in recovery stage［J］.Mod J Integr Tradit Chin West Med，2017，26（35）：3883-3885，3963.
  70. 70.
    LI L，GOU C Y，LI X M，et al.Effects of Chinese medicine on symptoms，syndrome evolution，and lung inflammation absorption in COVID-19 convalescent patients during 84-day follow-up after hospital discharge：A prospective cohort and nested case-control study［J］.Chin J Integr Med，2021，27（4）：245-251.
  71. 71.
    CHEN Y，LIU C，WANG T，et al.Efficacy and safety of Bufei Huoxue capsules in the management of convalescent patients with COVID-19 infection：A multicentre，double-blind，and randomised controlled trial［J］.J Ethnopharmacol，2022，284：114830.
  72. 72.
    LI W K，YANG J，CHEN R Y，et al.Clinical efficacy study of Bufei Huoxue capsules in treatment of SARS-CoV-2 infection recovery phase with qi deficiency and blood stasis syndrome［J］.Chin Tradit Herb Drug，2024，55（3）：872-881.
  73. 73.
    LIU X R，PAN Y，ZHANG J Y，et al.Clinical study on the treatment of children pneumonia convalescent period with Yiqi Jianpi Huoxue method［J］.Clin J Tradit Chin Med，2014，26（12）：1243-1244.
  74. 74.
    TIAN X R，LI X Z，ZHU J，et al.Effect of Tongfu Yiqi Huoxue decoction combined with alveolar lavage in the treatment of pneumonia sepsis and its influence on T lymphocyte subsets and mitochondrial damage index［J］.Hainan Med J，2024，35（1）：29-34.

Lire l'article complet

The above content is generated by Large Model Translation. The translated content is for reference only. We do not assume any commercial or legal responsibilty for any consequences arising from the use of our website